ReviewCancer metastasis reviews2026
Homeobox A10 in gastrointestinal malignancies: unraveling metastatic mechanisms and novel therapeutic opportunities.
Sophia G Kisling, Ashu Shah, Esther Johnson, Zahraa W Alsafwani, Venu Raman, Surinder K Batra
Abstract readReview
In one paragraphReview in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Sophia G KislingDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA.
Ashu ShahDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA. ashu.shah@unmc.edu.
Esther JohnsonDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA.
Zahraa W AlsafwaniDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA.
Venu RamanDepartment of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA. sbatra@unmc.edu.
Funding
Validation of biomarkers for risk prediction and early diagnosis of Pancreatic AdenocarcinomaU01CA200466 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Surinder K. Batra, Randall Brand · 2016 to 2026
$11.3MProject 3: MUC16-Mediated Metabolic Reprograming Induces PC MetastasisP01CA217798 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI THAYER, SARAH P · 2018 to 2022
$8.1MUrine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancerR01CA254036 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BATRA, SURINDER K., BRAND, RANDALL · 2021 to 2025
$3.1MModulation of Tumor Microenvironment for Improved Therapy of Pancreatic CancerR01CA247471 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., JAIN, MANEESH · 2020 to 2024
$2.8MTruncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancerR01CA273349 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., PONNUSAMY, MOORTHY P. · 2022 to 2025
$2.7MMolecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic CancerR01CA256973 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Surinder K. Batra, Michael Bouvet · 2022 to 2026
$2.2MConnectivity mapping identified novel combination therapy for glioblastomaR01CA273319 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., SHONKA, NICOLE · 2022 to 2025
$2.2MNovel Therapy to Inhibit IPMN ProgressionR01CA263575 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI BATRA, SURINDER K., MALAFA, MOKENGE P. · 2022 to 2024
$2.1MNCI NIH HHS P01 CA217798NCI NIH HHS R01 CA247471NCI NIH HHS R01 CA254036NCI NIH HHS R01 CA256973NCI NIH HHS R01 CA263575NCI NIH HHS R01 CA273319NCI NIH HHS R01 CA273349NCI NIH HHS U01 CA200466
6 · The paper itselfAbstract
Homeobox (HOX) genes are essential regulators of embryonic development and cellular differentiation under physiological conditions. Among this gene family, HOXA10 has emerged as a pivotal factor in gastrointestinal (GI) cancers, influencing tumor growth, metastasis, disease progression, and resistance to therapy. HOXA10 functions as a transcription factor and plays key roles not only in embryogenesis but also in immunomodulation. HOXA10 and its transcriptional targets play a crucial role in cancer development, promoting cell growth, invasion, migration, metastasis, and resistance to cell death. Recent studies have explored the influence of HOXA10 on the tumor immune microenvironment, particularly its role in modulating immune cell recruitment and signaling pathways that enable tumor immune evasion. Our recent research identified a HOXA10-regulated five-gene signature that distinguishes long-term from short-term survivors of pancreatic cancer, with HOXA10 expression correlating with increased regulatory T cell (T
Indexed as
Gastrointestinal NeoplasmsHomeobox A10 ProteinsHomeodomain ProteinsAnimalsGene Expression Regulation, NeoplasticHumansNeoplasm MetastasisTumor MicroenvironmentHomeobox A10 ProteinsHomeodomain ProteinsHOXA10 protein, humanCancerCell signalingHomeobox genesHOXA10Tumor immune microenvironment
Identifiers
PMID42098518
PMCPMC13617773
What OpenQuestion holds
Textmetadata
Read underepoch 390